ProBioGen invests €20m in mammalian manufacturing expansion

Announcement coincides with company's twentieth anniversary

ProBioGen, a specialist in the development and manufacturing of complex therapeutic glycoproteins and viral vaccines, is to planning to double its workforce and invest €20m at its site in Berlin, Germany.

'With an investment of around €20m we will strengthen our market position, add two additional disposable 1000L bioreactors and, within the next two years, will double our staff from currently 75 highly skilled and dedicated employees,' said CEO Dr Wieland Wolf.

ProBioGen is developing novel biotechnological processes for the production of biopharmaceutical drug substances to treat serious diseases on behalf of pharmaceutical and biotech companies. The service spectrum ranges from cell line and process development up to GMP contract manufacturing.

In addition, the Berlin scientists develop innovative technologies to improve biotechnologically active substances and have created an extensive portfolio of proprietary rights for optimised biopharmaceutical manufacturing. Licences have recently been granted to a number of global pharmaceutical companies, including Boehringer Ingelheim and Novartis.

Companies